USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) Director Peggie Pelosi sold 780 shares of USANA Health Sciences stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $28.10, for a total transaction of $21,918.00. Following the completion of the transaction, the director now owns 3,395 shares of the company's stock, valued at $95,399.50. This represents a 18.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
USANA Health Sciences Price Performance
NYSE USNA traded up $1.61 during trading on Thursday, reaching $32.48. The company's stock had a trading volume of 218,750 shares, compared to its average volume of 174,810. The firm has a fifty day moving average of $33.09 and a 200 day moving average of $36.30. USANA Health Sciences, Inc. has a one year low of $27.71 and a one year high of $50.32. The stock has a market capitalization of $618.99 million, a PE ratio of 11.48, a P/E/G ratio of 0.93 and a beta of 0.98.
USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.49 by $0.15. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The business had revenue of $213.61 million for the quarter, compared to the consensus estimate of $208.82 million. Research analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Creative Planning bought a new stake in USANA Health Sciences during the third quarter worth about $394,000. Harbor Capital Advisors Inc. boosted its stake in USANA Health Sciences by 44.1% in the third quarter. Harbor Capital Advisors Inc. now owns 8,859 shares of the company's stock worth $336,000 after buying an additional 2,713 shares in the last quarter. KBC Group NV grew its position in USANA Health Sciences by 96.6% during the third quarter. KBC Group NV now owns 1,056 shares of the company's stock valued at $40,000 after acquiring an additional 519 shares during the last quarter. Royce & Associates LP raised its stake in shares of USANA Health Sciences by 22.2% during the third quarter. Royce & Associates LP now owns 33,143 shares of the company's stock worth $1,257,000 after acquiring an additional 6,031 shares in the last quarter. Finally, Quest Partners LLC bought a new stake in shares of USANA Health Sciences in the 3rd quarter worth approximately $250,000. 54.25% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
USNA has been the subject of several analyst reports. StockNews.com downgraded USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th. DA Davidson cut their price objective on shares of USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating for the company in a research report on Thursday, February 27th. Finally, Sidoti lowered shares of USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, February 18th.
Check Out Our Latest Stock Report on USANA Health Sciences
About USANA Health Sciences
(
Get Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Featured Stories

Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.